Back
Protagonist Therapeutics 10K Form
Buy
56
PTGX
Protagonist Therapeutics
Last Price:
47.64
Seasonality Move:
13.55%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-02 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2023-08-03 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2023-05-04 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2022-11-08 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2022-08-04 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2022-05-05 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
Receive PTGX News And Ratings
See the #1 stock for the next 7 days that we like better than PTGX
PTGX Financial Statistics
Sales & Book Value
| Annual Sales: | $60M |
|---|---|
| Cash Flow: | $268.59M |
| Price / Cash Flow: | 12.61 |
| Annual Sales: | $9.21 |
| Price / Book: | 5.18 |
Profitability
| EPS (TTM): | 2.62000 |
|---|---|
| Net Income (TTM): | $169.95M |
| Gross Margin: | -- |
| Return on Equity: | 41.77% |
| Return on Assets: | 37.73% |
Protagonist Therapeutics Earnings Forecast
Key Protagonist Therapeutics Financial Ratios
- The Research & Development expenses have been 200.27% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of PTGX is -131.59% of Total Revenues.
- Per Share Earnings over the last 10 years have been positive in 5 years.
Protagonist Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | PTGX |
| CUSIP: | 74366E |
| Website: | protagonist-inc.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 13.73 |
| Quick Ratio: | 13.6 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
PTGX Technical Analysis vs Fundamental Analysis
Buy
56
Protagonist Therapeutics (PTGX)
is a Buy
Is Protagonist Therapeutics a Buy or a Sell?
-
Protagonist Therapeutics stock is rated a Buy
The current Protagonist Therapeutics [PTGX] share price is $47.64. The Score for PTGX is 56, which is 12% above its historic median score of 50, and infers lower risk than normal.